Hemogenyx Pharmaceuticals is a UK-based preclinical-stage biotech company focused on developing therapies and treatments for blood diseases, particularly for the bone marrow/hematopoietic stem cell transplant market. The company's products target acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, amongst others. Hemogenyx is also developing chimeric antigen receptor T-cells for use in immunotherapy, and stem cell therapy products for bone marrow transplants. Hemogenyx has a collaboration with GlobalCo and was incorporated in 2013.